#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
CB2 receptor activation appears to mediate resistance to trastuzumab (Herceptin), a standard HER2-positive breast cancer treatment, which could explain why some patients fail to respond to this therapy and inform strategies to overcome treatment resistance. Clinicians managing HER2-positive breast cancer patients may need to consider CB2 modulation as a potential adjunct therapy or biomarker for predicting trastuzumab response. This finding opens a pathway for developing combination treatments that target both HER2 and the CB2 receptor to improve outcomes in resistant cases.
# Clinical Summary Recent preclinical research has identified cannabinoid receptor 2 (CB2R) as a potential mediator of trastuzumab resistance in HER2-positive breast cancer cells, suggesting that CB2R activation may limit the therapeutic efficacy of this widely used monoclonal antibody. This finding emerges from investigations into the endocannabinoid system’s role in cancer cell biology and immune modulation, demonstrating a previously unrecognized interaction between cannabinoid signaling and established cancer therapy mechanisms. While this work is currently at the basic science stage and requires further validation in animal models and clinical settings, it raises important questions about potential drug-drug interactions or patient outcomes in cannabis-using populations undergoing trastuzumab therapy. Clinicians treating HER2-positive breast cancer patients who use cannabis or cannabinoid products should be aware of this emerging evidence and consider discussing cannabis use during treatment planning, particularly as more clinical data become available. The practical implication for clinicians is to document cannabis use in patients receiving trastuzumab and to monitor treatment response closely while remaining alert to future clinical guidance on managing this potential interaction.
“The early signals here are worth watching—we’re seeing in vitro work suggesting CB2 receptor involvement in trastuzumab resistance, which could eventually open new therapeutic avenues—but we need to see this replicated in human cancer models and ultimately in clinical trials before we can draw any conclusions about clinical utility.”
💊 While emerging preclinical data suggest that cannabinoid receptor CB2 may play a role in trastuzumab resistance in certain breast cancer models, clinicians should exercise caution before incorporating cannabis or CB2-targeted therapies into oncology practice. The translation from in vitro findings to clinical benefit remains uncertain, and the endocannabinoid system’s complex role in immune regulation and tumor biology means that CB2 modulation could have unpredictable effects across different cancer types and patient populations. Current evidence does not support cannabis use as an adjunctive treatment to overcome HER2-targeted therapy resistance, and patients taking cannabis alongside trastuzumab may face unexamined drug interactions or immunomodulatory effects that could compromise their primary cancer treatment. For now, oncologists should acknowledge these emerging mechanistic insights while maintaining adherence to established treatment protocols and advising patients against self-directed cannabinoid use outside of
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
